title: Steroidal regulation of endometriosis tissue: lack of induction of 17 beta-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol.
abstract: Cytosol and nuclear estrogen receptors were detected in 73% and 89% of untreated endometriosis specimens, respectively. The corresponding figures for cytosol and nuclear progestin receptors were 94% and 100%, respectively. Compared with the endometrium, the concentrations in endometriosis tissue were low. The anatomic site, the severity of the disease, and the phase of the menstrual cycle had no significant influence on receptor concentrations in endometriosis tissue. The activities of 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) did not increase during the luteal phase. Danazol for 1, 3, 7 to 11, and 18 to 30 days, or medroxyprogesterone acetate for 5 days, had no effect on receptor concentrations or 17 beta-HSD activity in endometriosis tissue. The frequent presence of the receptors suggests that endometriosis lesions are under the control of steroid hormones. The lack of effect by progesterone and progestins on 17 beta-HSD shows that this regulation is different in endometriosis tissue and in the endometrium.
authors.forename: P
authors.initials: P
authors.lastname: Vierikko
authors.forename: A
authors.initials: A
authors.lastname: Kauppila
authors.forename: L
authors.initials: L
authors.lastname: Rönnberg
authors.forename: R
authors.initials: R
authors.lastname: Vihko
mesh_terms: D015067:17-Hydroxysteroid Dehydrogenases / Q000096:biosynthesis*; D000328:Adult; D002467:Cell Nucleus / Q000032:analysis; D003600:Cytosol / Q000032:analysis; D003613:Danazol / Q000494:pharmacology* / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology*; D004717:Endometrium / Q000201:enzymology / Q000503:physiopathology; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D011245:Pregnadienes / Q000494:pharmacology*; D011374:Progesterone / Q000494:pharmacology* / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000032:analysis / Q000187:drug effects; D011980:Receptors, Progesterone / Q000032:analysis / Q000187:drug effects
chemical_list: D011245:Pregnadienes; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D011374:Progesterone; D017258:Medroxyprogesterone Acetate; D015067:17-Hydroxysteroid Dehydrogenases; D008525:Medroxyprogesterone; D003613:Danazol